Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00868036 · ClinicalTrials.gov registry record

Evaluating for Contact Allergies in Patients With Chronic Urticaria

A clinical trial of Allergy and Dermatitis, sponsored by Tufts Medical Center.

Completed
Registry status
23
Enrollment target
1
Study location

NCT00868036: Completed study of Allergy and Dermatitis, sponsored by Tufts Medical Center.

NCT00868036 is a study of Allergy and Dermatitis that has completed, run by Tufts Medical Center. The registered enrollment target is 23 participants, below the 331-participant average among 15 other Allergy trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00868036, a study of Allergy and Dermatitis, has completed, sponsored by Tufts Medical Center.

COMPLETED
Registry status
23 participants
Enrollment target
1
Study location

Study Summary

Hives affects 10-25% of the population worldwide at some time during their lifetime. Hives are itchy transient swellings of the skin lasting 4-36 hours. Chronic urticaria is defined as hives that have been ongoing for six weeks or more. Patch testing is performed to diagnose allergic contact dermatitis, and if contact allergens are found via patch testing, patients can often be cured of their dermatitis. However, patch testing is currently not routinely performed in the evaluation of patients with chronic idiopathic urticaria. Our hypothesis is to see if contact allergens can be identified with patch testing in patients with chronic urticaria, and, if any allergens are identified, to see if avoiding these contact allergens will make the chronic urticaria go away.

Interventions

  • PROCEDURE Patch Testing

Study Locations (1)

Massachusetts

  • Tufts Medical Center, Department of Dermatology - Boston

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2008-12
Est. Completion 2011-01
Tufts Medical Center

169 total trials

What the finished NCT00868036 record still lists

NCT00868036 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 331-participant average among 15 other Allergy trials with a reported enrollment target (93% lower).

The record links to 5 conditions, with Allergy appearing as the primary indexed condition, and to 1 intervention - of which Patch Testing is the first listed.

NCT00868036 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00868036 about?

NCT00868036 is a clinical study titled "Evaluating for Contact Allergies in Patients With Chronic Urticaria". Hives affects 10-25% of the population worldwide at some time during their lifetime. Hives are itchy transient swellings of the skin lasting 4-36 hours. Chronic urticaria is defined as hives that have been ongoing for six weeks or more. Patch testing is performed to diagnose allergic contact dermat...

What is the current status of trial NCT00868036?

This trial is currently completed. The enrollment target is 23 participants. The study started on 2008-12. Estimated completion is 2011-01.

What conditions does trial NCT00868036 study?

This clinical trial studies the following conditions: Allergy, Dermatitis, Urticaria, Patch Testing, Contact Sensitization.

What interventions are being tested in trial NCT00868036?

The interventions under investigation include: Patch Testing (PROCEDURE).

Who is sponsoring clinical trial NCT00868036?

This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00868036 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Allergy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00868036's enrollment target sits among peer trials

23 14th of 15 higher than 2 of 15 other Allergy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Allergy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03616041 · 23 participants

    Capsule Endoscopy for Severe Hematochezia

  • NCT04348747 · 23 participants · Phase 2

    Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

  • NCT04587687 · 23 participants · Phase 2

    Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

  • NCT04715022 · 23 participants · Phase 1

    Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00868036, the US trial registry maintained by the National Library of Medicine. NCT00868036 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.